Why the study?
Do soluble epoxide hydrolase (sEH) inhibitors prevent detrimental cardiac remodeling and heart failure in animal models?
Population
Animal models of cardiovascular disease including hypertension, cardiac hypertrophy, and…
Design
Review
Authors
Loading...
sEH inhibitors show preclinical promise in HF remodeling; leaves open translation to human trials.
Do soluble epoxide hydrolase (sEH) inhibitors prevent detrimental cardiac remodeling and heart failure in animal models?
Preclinical data suggest that sEH inhibitors represent a promising therapeutic approach for combating detrimental cardiac remodeling and heart failure.
Qiu et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: